TherapeuticsMD, Inc. (NASDAQ:TXMD) saw unusually large options trading on Friday. Stock investors purchased 2,623 put options on the company. This represents an increase of approximately 868% compared to the typical volume of 271 put options.
A number of brokerages have recently issued reports on TXMD. BidaskClub cut TherapeuticsMD from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. Jefferies Group restated a “buy” rating and set a $15.00 price objective on shares of TherapeuticsMD in a report on Tuesday, September 26th. Deutsche Bank set a $10.00 price target on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Tuesday, August 22nd. Oppenheimer reiterated an “outperform” rating and issued a $10.00 price target on shares of TherapeuticsMD in a research report on Thursday, August 31st. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $31.00 price target on shares of TherapeuticsMD in a research report on Wednesday, November 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $15.00.
In other news, Director Tommy G. Thompson acquired 5,000 shares of TherapeuticsMD stock in a transaction dated Friday, December 8th. The stock was bought at an average price of $6.21 per share, for a total transaction of $31,050.00. Following the completion of the acquisition, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 23.92% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Candriam Luxembourg S.C.A. raised its position in TherapeuticsMD by 10.4% during the third quarter. Candriam Luxembourg S.C.A. now owns 530,000 shares of the company’s stock valued at $2,804,000 after purchasing an additional 50,000 shares in the last quarter. Schwab Charles Investment Management Inc. raised its position in TherapeuticsMD by 10.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 694,167 shares of the company’s stock valued at $3,659,000 after purchasing an additional 67,855 shares in the last quarter. Swiss National Bank raised its position in TherapeuticsMD by 12.3% during the third quarter. Swiss National Bank now owns 289,800 shares of the company’s stock valued at $1,533,000 after purchasing an additional 31,800 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its position in TherapeuticsMD by 293.0% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 112,900 shares of the company’s stock valued at $595,000 after purchasing an additional 84,170 shares in the last quarter. Finally, Stifel Financial Corp raised its position in TherapeuticsMD by 377.9% during the second quarter. Stifel Financial Corp now owns 2,052,030 shares of the company’s stock valued at $10,820,000 after purchasing an additional 1,622,668 shares in the last quarter. Institutional investors own 73.69% of the company’s stock.
Shares of TherapeuticsMD (TXMD) opened at $6.17 on Wednesday. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The company had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. During the same period in the previous year, the business earned ($0.13) earnings per share. The firm’s quarterly revenue was down 19.7% on a year-over-year basis. sell-side analysts expect that TherapeuticsMD will post -0.37 earnings per share for the current fiscal year.
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.